E-Submission
Yeungnam University College of MedicineIndexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
Search
- Page Path
- HOME > Search
Case report
- Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
- Min Kyu Kang, Heon Ju Lee, Joon Hyuk Choi
- Yeungnam Univ J Med. 2019;36(2):155-158. Published online January 21, 2019
- DOI: https://doi.org/10.12701/yujm.2019.00115
- 4,903 View
- 83 Download
- 2 Crossref
-
Abstract
PDF - Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare. Its features vary from subclinical elevation of serum aminotransferase to clinically apparent acute hepatitis, which is associated with immunologic reactions. Imatinib-induced hepatotoxicity with autoimmune-like features can be treated by the discontinuation of imatinib mesylate and the administration of oral steroids. Here, we report a case of late-onset imatinib-induced hepatitis with autoimmune-like features in a patient with metastatic GIST, which was improved by oral corticosteroids.
-
Citations
Citations to this article as recorded by
- The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review
Mansour Tobaiqy, Nawal Helmi, Katie MacLure, Sylvia Saade
International Journal of Clinical Pharmacy.2024; 46(2): 368. CrossRef - Antioxidant-Based Preventive Effect of Phytochemicals on Anticancer Drug-Induced Hepatotoxicity
Ji Eon Park, Chi-Hoon Ahn, Hyo-Jung Lee, Deok Yong Sim, Su Yeon Park, Bonglee Kim, Bum Sang Shim, Dae Young Lee, Sung-Hoon Kim
Antioxidants & Redox Signaling.2023;[Epub] CrossRef
- The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review
First
Prev
